Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

ROIV

Roivant Sciences Ltd

Oct 30 • 12:00PM ET

19.25

+0.49 2.59 %

Healthcare • Biotechnology • United Kingdom • NASD

Peers: VRTX REGN BIIB BMRN ALNY CRSP INCY NBIX IONS EDIT

| Held by: IJH VTI VB XBI VBK VXF MDY IBB IJK SPMD

Index	-	P/E	-	EPS (ttm)	-0.70	Insider Own	39.18%	Shs Outstand	682.23M	Perf Week	6.21%
Market Cap	13.14B	Forward P/E	-	EPS next Y	-1.39	Insider Trans	-3.36%	Shs Float	415.35M	Perf Month	22.19%
Enterprise Value	9.21B	PEG	-	EPS next Q	-0.32	Inst Own	64.10%	Short Float	6.08%	Perf Quarter	70.16%
Income	-490.63M	P/S	565.74	EPS this Y	-430.71%	Inst Trans	-5.18%	Short Ratio	3.47	Perf Half Y	66.19%
Sales	23.23M	P/B	3.02	EPS next Y	-8.98%	ROA	-13.44%	Short Interest	25.27M	Perf YTD	62.68%
Book/sh	6.37	P/C	2.92	EPS next 5Y	-	ROE	-15.84%	52W High	18.95 1.53%	Perf Year	62.54%
Cash/sh	6.60	P/FCF	-	EPS past 3/5Y	42.73% -99.51%	ROIC	-11.06%	52W Low	8.73 120.45%	Perf 3Y	302.62%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-19.30% -	Gross Margin	96.33%	Volatility	3.05% 3.25%	Perf 5Y	-
Dividend TTM	-	EV/Sales	396.32	EPS Y/Y TTM	-111.82%	Oper. Margin	-5104.73%	ATR (14)	0.52	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	40.54	Sales Y/Y TTM	-85.32%	Profit Margin	-2111.79%	RSI (14)	83.85	Recom	1.17
Dividend Gr. 3/5Y	- -	Current Ratio	40.54	EPS Q/Q	-369.32%	SMA20	11.29%	Beta	1.23	Target Price	20.75
Payout	-	Debt/Eq	0.02	Sales Q/Q	-96.06%	SMA50	26.94%	Rel Volume	1.77	Prev Close	18.76
Employees	750	LT Debt/Eq	0.02	Earnings	Nov 10 BMO	SMA200	60.34%	Avg Volume	7.28M	Price	19.25
IPO	Dec 08, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-0.84% -70.28%	Trades		Volume	5,358,712	Change	2.59%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-02-25	Initiated	Citigroup	Buy	$16
Jul-10-25	Resumed	Goldman	Buy	$19
Feb-15-24	Initiated	Wolfe Research	Outperform	$17
Jan-05-24	Initiated	Piper Sandler	Overweight	$20
Dec-12-23	Initiated	Deutsche Bank	Buy	$14
Oct-17-23	Initiated	Guggenheim	Buy	$17
Jun-08-23	Initiated	BofA Securities	Neutral	$10.50
Oct-27-22	Initiated	JP Morgan	Overweight	$7
May-23-22	Initiated	SVB Leerink	Outperform	$6
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-15-21	Initiated	Goldman	Buy	$15
Nov-08-21	Initiated	H.C. Wainwright	Buy	$14
Oct-28-21	Initiated	Citigroup	Buy	$11
Oct-26-21	Initiated	Truist	Buy	$15
Oct-26-21	Initiated	Jefferies	Buy	$10
Oct-26-21	Initiated	Cowen	Outperform

Show Previous Ratings

Oct-27-25 04:10PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 (GlobeNewswire)
Oct-21-25 05:52AM	Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) (Insider Monkey)
Oct-04-25 04:54PM	Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints (Insider Monkey)
Sep-29-25 08:01PM	Vivek Ramaswamy's Bitcoin Play Just Got Bigger: This $1.3B Deal Could Signal Corporate Crypto's Next Phase (Benzinga)
Sep-23-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice (Zacks)
10:21AM	Loading…
Sep-22-25 10:21AM	Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings (Reuters)
Sep-18-25 10:47AM	Roivant Sciences (ROIV) Hits New All-Time High as Drug Candidate Clinical Trial Posts Impressive Results (Insider Monkey)
10:34AM	Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains? (Zacks)
Sep-17-25 04:11PM	Roivant Flirts With A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease (Investor's Business Daily) +7.76%
12:49PM	Why Roivant Sciences Stock Is Soaring Today (Motley Fool)
07:00AM	Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) (GlobeNewswire)
Sep-14-25 04:00AM	Vivek Ramaswamy Sells $22.7 Million of Roivant Sciences Stock (Barrons.com)
Sep-11-25 04:30PM	Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List (GlobeNewswire)
11:11AM	Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat (Insider Monkey)
Sep-03-25 01:01PM	Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients (GlobeNewswire)
11:49PM	Loading…
Aug-28-25 11:49PM	Roivant Sciences (ROIV) Announces Q1 2025 Business Update (Insider Monkey)
Aug-12-25 06:42PM	Why Roivant Sciences Stock Bounced Back on Tuesday (Motley Fool)
03:02AM	Roivant Sciences Ltd (ROIV) Q1 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Aug-11-25 04:58PM	Why Roivant Sciences Stock Was Slipping on Monday (Motley Fool)
08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update (GlobeNewswire)
Aug-08-25 09:17AM	What To Expect From Roivant Sciences Ltd (ROIV) Q1 2026 Earnings (GuruFocus.com)
Aug-07-25 06:15PM	Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-05-25 08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-28-25 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025 (GlobeNewswire)
Jul-24-25 11:47PM	Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with 'Buy' Rating (Insider Monkey)
Jul-11-25 06:20AM	Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar? (Zacks)
Jun-24-25 12:45PM	Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat (Insider Monkey)
Jun-16-25 07:00AM	Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics (GlobeNewswire)
Jun-09-25 04:05PM	Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis (GlobeNewswire)
08:15AM	Loading…
May-29-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +6.40%
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update (GlobeNewswire)
May-28-25 02:17PM	H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock (Insider Monkey)
09:15AM	What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings (GuruFocus.com)
May-15-25 05:15PM	Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:10PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025 (GlobeNewswire)
May-14-25 05:40PM	Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-13-25 05:10PM	Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-08-25 07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 06:20AM	Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar? (Zacks)
May-02-25 10:37AM	Roivant Sciences Ltd. (ROIV): Among David Einhorn's Stock Picks with Huge Upside Potential (Insider Monkey)
Apr-29-25 11:35AM	Roivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
Apr-23-25 12:13PM	Roivant Sciences: Primed For Growth With A De-Risked Pipeline (Seeking Alpha)
Apr-21-25 04:08PM	Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug (Investor's Business Daily)
10:18AM	Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift (Investor's Business Daily)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjogren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sj gren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
Apr-14-25 06:20AM	Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now? (Zacks)
Apr-11-25 03:07PM	Is Roivant Sciences Ltd. (ROIV) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
10:04AM	Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-10-25 05:08PM	Roivant Sciences Ltd. (ROIV): Among the Best Low Priced Growth Stocks to Invest In (Insider Monkey)
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
Mar-29-25 04:00PM	Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy? (Insider Monkey)
Mar-25-25 02:12PM	Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn? (InsiderMonkey)
Mar-19-25 04:04PM	Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. (Investor's Business Daily)
09:26AM	Roivant, Immunovant Succeed In Phase 3. But There's A Twist And Shares Tumbled. (Investor's Business Daily)
07:45AM	Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies (GlobeNewswire)
Mar-18-25 04:32PM	Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs (GlobeNewswire)
Mar-03-25 09:15AM	Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna (GlobeNewswire) -5.31%
Feb-25-25 08:00AM	Early Warning Report Issued Pursuant to National Instrument 62 103: Roivant announces Resignation and Replacement of Arbutus Board (GlobeNewswire)
Feb-12-25 10:00AM	Roivant Sciences price target lowered to $12 from $13 at BofA (TipRanks)
Feb-10-25 07:00AM	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update (GlobeNewswire)
Feb-07-25 07:06AM	What To Expect From Roivant Sciences Ltd (ROIV) Q3 2025 Earnings (GuruFocus.com)
Feb-03-25 07:00AM	Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care (GlobeNewswire)
Jan-29-25 04:05PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025 (GlobeNewswire)
Jan-15-25 08:49PM	Vivek Ramaswamy Open to Replacing JD Vance in Senateif Offered (The Wall Street Journal)
Jan-12-25 09:40AM	Is Roivant Sciences (ROIV) the Best Medical Stock to Buy Under $20? (Insider Monkey)
Jan-02-25 03:28AM	Why Roivant Sciences Ltd. (ROIV) Is Skyrocketing (Insider Monkey)
Dec-03-24 07:00AM	Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis (GlobeNewswire)
07:00AM	Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis (GlobeNewswire)
Nov-15-24 05:01PM	Vivek Ramaswamy's Net Worth Is 9 Figures See How the DOGE Co-Lead Made His Millions (Investopedia)
Nov-12-24 07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update (GlobeNewswire)
Nov-11-24 07:04AM	Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-24 04:35PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024 (GlobeNewswire)
Oct-28-24 09:25AM	Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1% (GlobeNewswire)
Sep-18-24 07:30AM	Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1% (GlobeNewswire)
Sep-10-24 06:30AM	Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator (GlobeNewswire)
06:30AM	Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress (GlobeNewswire)
Sep-09-24 07:00AM	Roivant Provides Update on Graves' Disease Development Program (GlobeNewswire)
Sep-04-24 06:55PM	The Federal Reserve should refresh its mandate: Former presidential candidate Vivek Ramaswamy (Yahoo Finance)
Aug-08-24 07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update (GlobeNewswire) +6.69%
Jul-25-24 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024 (GlobeNewswire)
May-31-24 08:04AM	Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript (Insider Monkey)
May-30-24 11:53AM	ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace)
08:20AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update (GlobeNewswire)
May-27-24 06:28PM	Institutional Investors are Betting on Roivant Sciences (NASDAQ:ROIV) (Insider Monkey)
06:13PM	7 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
May-16-24 04:05PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 (GlobeNewswire)
May-08-24 02:43AM	Greenlight Capital Initiated a Position in Roivant Sciences (ROIV) in Q1 (Insider Monkey)
May-07-24 02:04PM	Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare (InvestorPlace)
May-01-24 10:47AM	3 Healthcare Stocks With the Potential to Triple Your Investment by 2026 (InvestorPlace)
Apr-25-24 08:00AM	Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis (Business Wire)
Apr-12-24 11:09AM	10 Most Undervalued Stocks to Buy for Under $20 (Insider Monkey)
Apr-02-24 07:00AM	Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million (GlobeNewswire)
Mar-27-24 01:55PM	Stocks to Watch Wednesday: Carnival, Robinhood, Trump Media, Merck (The Wall Street Journal) +7.54%
Mar-26-24 06:22PM	Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600 (PR Newswire)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-14-24 07:04AM	10 Stocks George Soros and Insiders Are Crazy About (Insider Monkey)
Feb-15-24 02:45AM	Do You Think the Management of Roivant Sciences (ROIV) Can Create Value? (Insider Monkey)

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Venker Eric	President & Immunovant CEO	Oct 15 '25	Option Exercise	15.85	414,683	6,572,726	1,919,642	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 16 '25	Option Exercise	15.85	318,282	5,044,770	1,823,241	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 17 '25	Option Exercise	15.85	118,418	1,876,925	1,623,377	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 15 '25	Sale	16.93	414,683	7,020,583	1,504,959	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 16 '25	Sale	17.05	318,282	5,426,708	1,504,959	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 17 '25	Sale	17.06	118,418	2,020,211	1,504,959	Oct 17 09:00 PM
Venker Eric	Officer	Oct 17 '25	Proposed Sale	17.06	118,418	2,020,171		Oct 17 04:01 PM
Venker Eric	Officer	Oct 16 '25	Proposed Sale	17.05	318,282	5,425,645		Oct 16 04:37 PM
Venker Eric	Officer	Oct 15 '25	Proposed Sale	16.93	414,683	7,021,429		Oct 15 04:23 PM
Venker Eric	President & Immunovant CEO	Oct 09 '25	Option Exercise	15.85	104,940	1,663,299	1,609,899	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 13 '25	Option Exercise	15.85	20,727	328,523	1,525,686	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 09 '25	Sale	16.30	104,940	1,710,522	1,504,959	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 13 '25	Sale	16.25	20,727	336,814	1,504,959	Oct 14 09:00 PM
Venker Eric	Officer	Oct 13 '25	Proposed Sale	16.25	20,727	336,877		Oct 14 08:51 AM
Venker Eric	Officer	Oct 09 '25	Proposed Sale	16.30	104,940	1,710,040		Oct 09 04:12 PM
Venker Eric	President & Immunovant CEO	Oct 07 '25	Option Exercise	7.21	355,161	2,559,093	1,860,120	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 06 '25	Option Exercise	13.29	171,396	2,277,775	1,676,355	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 08 '25	Option Exercise	8.07	138,602	1,119,164	1,643,561	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 07 '25	Sale	16.15	355,161	5,735,850	1,504,959	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 06 '25	Sale	16.34	171,396	2,800,611	1,504,959	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 08 '25	Sale	16.20	138,602	2,245,352	1,504,959	Oct 08 09:00 PM
Venker Eric	Officer	Oct 08 '25	Proposed Sale	16.20	138,602	2,244,797		Oct 08 04:15 PM
Venker Eric	Officer	Oct 07 '25	Proposed Sale	16.15	355,161	5,734,289		Oct 07 04:34 PM
Venker Eric	Officer	Oct 06 '25	Proposed Sale	16.34	171,396	2,800,365		Oct 06 04:46 PM
Venker Eric	President & Immunovant CEO	Sep 19 '25	Option Exercise	3.85	1,000,000	3,850,000	2,653,585	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 22 '25	Option Exercise	3.85	562,374	2,165,140	2,532,141	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 19 '25	Sale	14.95	683,818	10,223,079	1,969,767	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 23 '25	Sale	14.83	611,000	9,061,130	1,504,959	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 22 '25	Sale	14.99	416,182	6,240,568	2,115,959	Sep 23 09:00 PM
Venker Eric	Officer	Sep 23 '25	Proposed Sale	14.94	611,079	9,129,520		Sep 23 09:45 AM
ERIC VENKER	Officer	Sep 22 '25	Proposed Sale	14.99	316,182	4,741,054		Sep 22 04:20 PM
Venker Eric	Officer	Sep 22 '25	Proposed Sale	15.01	100,000	1,501,339		Sep 22 04:07 PM
ERIC VENKER	Officer	Sep 19 '25	Proposed Sale	14.95	683,818	10,220,412		Sep 19 04:32 PM
Gline Matthew	CEO	Sep 18 '25	Buy	15.07	3,315	49,957	17,287,081	Sep 18 07:28 PM
Ramaswamy Vivek	10% Owner	Sep 03 '25	Sale	12.50	1,195,000	14,937,500	36,089,108	Sep 05 05:01 PM
Ramaswamy Vivek	10% Owner	Sep 05 '25	Sale	12.96	385,816	5,000,175	35,508,359	Sep 05 05:01 PM
Ramaswamy Vivek	10% Owner	Sep 04 '25	Sale	12.92	194,933	2,518,534	35,894,175	Sep 05 05:01 PM
Venker Eric	President & Immunovant CEO	Aug 20 '25	Option Exercise	3.85	100,000	385,000	1,753,585	Aug 22 09:00 PM
Venker Eric	President & Immunovant CEO	Aug 20 '25	Sale	11.72	100,000	1,172,000	1,653,585	Aug 22 09:00 PM
Venker Eric	Officer	Aug 20 '25	Proposed Sale	11.72	100,000	1,172,120		Aug 20 04:30 PM
Venker Eric	President & Immunovant CEO	Jul 21 '25	Option Exercise	3.85	100,000	385,000	1,562,223	Jul 23 09:00 PM
Venker Eric	President & Immunovant CEO	Jul 21 '25	Sale	11.52	100,000	1,152,000	1,462,223	Jul 23 09:00 PM
Venker Eric	Officer	Jul 21 '25	Proposed Sale	11.52	100,000	1,151,942		Jul 21 04:34 PM
Venker Eric	President & COO	Jun 20 '25	Option Exercise	3.85	100,000	385,000	1,562,223	Jun 24 09:01 PM
Venker Eric	President & COO	Jun 20 '25	Sale	11.45	100,000	1,145,000	1,462,223	Jun 24 09:01 PM
Ramaswamy Vivek	10% Owner	Jun 20 '25	Sale	11.46	577,007	6,612,500	37,284,108	Jun 23 11:35 AM
Ramaswamy Vivek	10% Owner	Jun 18 '25	Sale	11.45	565,266	6,472,296	37,861,115	Jun 23 11:35 AM
Ramaswamy Vivek	10% Owner	Jun 20 '25	Proposed Sale	11.46	577,007	6,611,850		Jun 20 04:35 PM
Venker Eric	Officer	Jun 20 '25	Proposed Sale	11.45	100,000	1,145,268		Jun 20 04:13 PM
Ramaswamy Vivek	10% Owner	Jun 18 '25	Proposed Sale	11.45	565,266	6,472,996		Jun 18 04:38 PM
Ramaswamy Vivek	10% Owner	Jun 04 '25	Sale	11.34	547,430	6,207,856	38,627,181	Jun 06 05:49 PM
Ramaswamy Vivek	10% Owner	Jun 06 '25	Sale	11.19	200,800	2,246,952	38,426,381	Jun 06 05:49 PM
Ramaswamy Vivek	10% Owner	Jun 06 '25	Proposed Sale	11.19	200,800	2,246,311		Jun 06 04:33 PM
Venker Eric	President & COO	Jun 03 '25	Option Exercise	3.85	785,026	3,022,350	2,028,501	Jun 04 09:00 PM
Venker Eric	President & COO	Jun 02 '25	Option Exercise	3.85	600,000	2,310,000	1,677,197	Jun 04 09:00 PM
Venker Eric	President & COO	Jun 03 '25	Sale	11.22	566,278	6,353,639	1,462,223	Jun 04 09:00 PM
Venker Eric	President & COO	Jun 02 '25	Sale	11.07	433,722	4,801,303	1,243,475	Jun 04 09:00 PM
Ramaswamy Vivek	10% Owner	Jun 04 '25	Proposed Sale	11.34	547,430	6,208,008		Jun 04 04:42 PM
ERIC VENKER	Officer	Jun 03 '25	Proposed Sale	11.22	566,278	6,355,961		Jun 03 05:14 PM
ERIC VENKER	Officer	Jun 02 '25	Proposed Sale	11.07	433,722	4,803,341		Jun 02 04:16 PM
Venker Eric	President & COO	May 20 '25	Option Exercise	3.85	100,000	385,000	1,177,197	May 22 09:00 PM
Venker Eric	President & COO	May 20 '25	Sale	10.95	100,000	1,095,000	1,077,197	May 22 09:00 PM
Venker Eric	Officer	May 20 '25	Proposed Sale	10.95	100,000	1,094,986		May 20 04:30 PM
Ramaswamy Vivek	10% Owner	May 07 '25	Sale	11.18	625,000	6,987,500	39,174,611	May 08 08:51 PM
Ramaswamy Vivek	10% Owner	May 06 '25	Sale	11.47	273,959	3,142,310	39,799,611	May 08 08:51 PM
Ramaswamy Vivek	10% Owner	May 07 '25	Proposed Sale	11.18	625,000	6,987,388		May 07 04:37 PM
Ramaswamy Vivek	10% Owner	May 06 '25	Proposed Sale	11.47	273,959	3,143,287		May 06 04:21 PM
Venker Eric	President & COO	Apr 21 '25	Option Exercise	3.85	100,000	385,000	1,216,345	Apr 22 09:00 PM
Venker Eric	President & COO	Apr 21 '25	Sale	10.22	100,000	1,022,000	1,116,345	Apr 22 09:00 PM
Venker Eric	Officer	Apr 21 '25	Proposed Sale	10.22	100,000	1,022,374		Apr 21 03:22 PM
Venker Eric	President & COO	Mar 24 '25	Option Exercise	3.85	602,311	2,318,897	1,561,768	Mar 24 09:21 PM
Venker Eric	President & COO	Mar 20 '25	Option Exercise	3.85	400,000	1,540,000	1,274,979	Mar 24 09:21 PM
Venker Eric	President & COO	Mar 24 '25	Sale	10.82	434,478	4,701,052	1,127,290	Mar 24 09:21 PM
Venker Eric	President & COO	Mar 20 '25	Sale	11.06	315,522	3,489,673	959,457	Mar 24 09:21 PM
Venker Eric	Officer	Mar 20 '25	Proposed Sale	10.95	650,000	7,117,500		Mar 20 05:27 PM
Venker Eric	Officer	Mar 20 '25	Proposed Sale	11.11	100,000	1,110,537		Mar 20 03:54 PM
Venker Eric	President & COO	Feb 20 '25	Option Exercise	3.85	100,000	385,000	996,869	Feb 24 09:00 PM
Venker Eric	President & COO	Feb 20 '25	Sale	10.65	100,000	1,065,000	896,869	Feb 24 09:00 PM
Venker Eric	Officer	Feb 20 '25	Proposed Sale	10.65	100,000	1,065,022		Feb 20 03:35 PM
Kumar Rakhi	Chief Accounting Officer	Feb 13 '25	Option Exercise	3.85	187,500	721,875	390,764	Feb 18 09:00 PM
Kumar Rakhi	Chief Accounting Officer	Feb 13 '25	Sale	10.43	227,500	2,372,825	163,264	Feb 18 09:00 PM
Venker Eric	President & COO	Feb 12 '25	Option Exercise	3.85	300,000	1,155,000	1,032,294	Feb 14 09:00 PM
Venker Eric	President & COO	Feb 13 '25	Option Exercise	3.85	300,000	1,155,000	1,114,910	Feb 14 09:00 PM
Venker Eric	President & COO	Feb 12 '25	Sale	10.53	217,384	2,289,054	732,294	Feb 14 09:00 PM
Venker Eric	President & COO	Feb 13 '25	Sale	10.42	218,041	2,271,987	896,869	Feb 14 09:00 PM
Kumar Rakhi	Officer	Feb 13 '25	Proposed Sale	10.43	227,500	2,372,966		Feb 13 05:14 PM
Venker Eric	Officer	Feb 12 '25	Proposed Sale	10.50	600,000	6,300,000		Feb 12 05:29 PM
Venker Eric	President & COO	Jan 21 '25	Option Exercise	3.85	100,000	385,000	832,294	Jan 22 09:04 PM
Venker Eric	President & COO	Jan 21 '25	Sale	11.28	100,000	1,128,000	732,294	Jan 22 09:04 PM
Venker Eric	Officer	Jan 21 '25	Proposed Sale	11.28	100,000	1,128,457		Jan 21 04:30 PM
Roivant Sciences Ltd.	Director	Jan 13 '25	Buy	20.00	16,845,010	336,900,200	96,650,341	Jan 15 04:36 PM
Venker Eric	President & COO	Dec 27 '24	Option Exercise	3.85	250,000	962,500	845,580	Dec 31 09:00 PM
Venker Eric	President & COO	Dec 30 '24	Option Exercise	3.85	250,000	962,500	918,680	Dec 31 09:00 PM
Venker Eric	President & COO	Dec 27 '24	Sale	11.82	176,900	2,090,958	668,680	Dec 31 09:00 PM
Venker Eric	President & COO	Dec 30 '24	Sale	11.54	177,704	2,050,704	740,976	Dec 31 09:00 PM
Venker Eric	Officer	Dec 27 '24	Proposed Sale	11.75	360,000	4,230,000		Dec 27 04:54 PM
Sukhatme Mayukh	Pres&Chief Investment Officer	Dec 26 '24	Option Exercise	3.85	689,495	2,654,556	19,526,042	Dec 26 09:00 PM
Sukhatme Mayukh	Pres&Chief Investment Officer	Dec 24 '24	Option Exercise	3.85	185,946	715,892	19,022,493	Dec 26 09:00 PM
Sukhatme Mayukh	Pres&Chief Investment Officer	Dec 23 '24	Option Exercise	3.85	10,796	41,565	18,847,343	Dec 26 09:00 PM
Sukhatme Mayukh	Pres&Chief Investment Officer	Dec 26 '24	Sale	12.01	689,495	8,280,835	18,836,547	Dec 26 09:00 PM

MP MP Materials Corporation daily Stock Chart

Peers: REE

| Held by: VTI IJH VB VBK XME VXF REMX ULTY MDY SPMD

Index	-	P/E	-	EPS (ttm)	-0.62	Insider Own	23.76%	Shs Outstand	163.47M	Perf Week	-5.40%
Market Cap	11.47B	Forward P/E	73.34	EPS next Y	0.88	Insider Trans	-0.41%	Shs Float	135.01M	Perf Month	-4.26%
Enterprise Value	11.63B	PEG	-	EPS next Q	-0.17	Inst Own	75.90%	Short Float	17.90%	Perf Quarter	1.67%
Income	-101.38M	P/S	47.36	EPS this Y	14.50%	Inst Trans	11.84%	Short Ratio	1.62	Perf Half Y	166.03%
Sales	242.12M	P/B	10.47	EPS next Y	334.69%	ROA	-4.31%	Short Interest	24.16M	Perf YTD	315.07%
Book/sh	6.18	P/C	15.20	EPS next 5Y	-	ROE	-9.57%	52W High	100.25 -35.41%	Perf Year	242.96%
Cash/sh	4.26	P/FCF	-	EPS past 3/5Y	- -41.29%	ROIC	-5.45%	52W Low	15.56 316.13%	Perf 3Y	104.71%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-15.00% 22.66%	Gross Margin	-23.66%	Volatility	5.44% 8.63%	Perf 5Y	385.02%
Dividend TTM	-	EV/Sales	48.04	EPS Y/Y TTM	-172.40%	Oper. Margin	-59.08%	ATR (14)	6.31	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.12	Sales Y/Y TTM	39.42%	Profit Margin	-41.87%	RSI (14)	40.88	Recom	1.94
Dividend Gr. 3/5Y	- -	Current Ratio	3.60	EPS Q/Q	8.54%	SMA20	-14.50%	Beta	2.26	Target Price	83.35
Payout	-	Debt/Eq	0.91	Sales Q/Q	83.61%	SMA50	-9.24%	Rel Volume	1.33	Prev Close	64.29
Employees	804	LT Debt/Eq	0.84	Earnings	Nov 06 AMC	SMA200	52.31%	Avg Volume	14.90M	Price	64.75
IPO	Jun 22, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	34.01% 24.39%	Trades		Volume	8,204,055	Change	0.72%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-09-25	Resumed	BMO Capital Markets	Market Perform	$76
Sep-23-25	Initiated	Daiwa Securities	Outperform	$80
Aug-01-25	Upgrade	Jefferies	Hold → Buy	$80
Jul-31-25	Resumed	Morgan Stanley	Equal-Weight	$65
Jul-07-25	Downgrade	Jefferies	Buy → Hold	$33
Jun-05-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$34
Sep-27-24	Reiterated	Robert W. Baird	Outperform	$20 → $25
Jul-15-24	Initiated	BMO Capital Markets	Market Perform	$16.50
Apr-23-24	Downgrade	JP Morgan	Overweight → Neutral	$20 → $16
Mar-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$26 → $15.50
Sep-06-23	Upgrade	Northland Capital	Market Perform → Outperform
Aug-31-23	Initiated	JP Morgan	Overweight	$27
Apr-18-23	Downgrade	Northland Capital	Outperform → Market Perform	$32
Jul-13-22	Initiated	Canaccord Genuity	Buy	$44
Jun-06-22	Resumed	Northland Capital	Outperform	$60
Jun-01-22	Initiated	BMO Capital Markets	Outperform	$50
Feb-09-22	Upgrade	The Benchmark Company	Hold → Buy	$47
Nov-30-21	Resumed	BofA Securities	Buy	$52
Nov-11-21	Initiated	The Benchmark Company	Hold
Nov-11-21	Initiated	Jefferies	Buy	$55

Show Previous Ratings

Today 11:30AM	Comcast, Stellantis, rare earth stocks: Trending Tickers (Yahoo Finance Video)
10:41AM	Trump-Xi Trade Truce Leaves Questions; Rare Earth Stocks Fall (Investor's Business Daily)
10:40AM	Trump and Xi Reach Rare-Earths Deal. Why MP Materials Stock Is Falling. (Barrons.com)
10:00AM	MP Materials Corp. (MP) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
09:37AM	Trump-Xi Trade Truce Leaves Questions; Rare Earth Stocks Rise (Investor's Business Daily)
07:00AM	Loading…
07:00AM	Washingtons $200 Million Move to Rebuild Americas Rare Earth Supply Chain (Oilprice.com)
06:18AM	Trump and Xi Reach Rare-Earths Deal. Why MP Materials Stock Is Rising. (Barrons.com)
Oct-29-25 05:00PM	Trump Signs Flurry Of Rare Earths Deals In Asia (Oilprice.com)
06:43AM	Rare-Earths Stocks Rise Ahead of Trump, Xi Meeting. Why a Bad Week Can Still Come Good. (Barrons.com)
Oct-28-25 04:39PM	Rare Earth Stocks Fall. This U.S. Company Has a Plan to Cut China Dependence. (Barrons.com)
04:05PM	MP Materials to Participate in Upcoming Conferences (Business Wire)
11:51AM	Dear MP Materials Stock Fans, Mark Your Calendars for October 30 (Barchart)
09:26AM	Don't Fear the Dip: Rare Earth Stocks May Rebound Fast (MarketBeat)
07:48AM	Forget the Tech Boom: This Miner Is Up 300% in 2025 (Motley Fool)
05:25AM	Rare-Earths Stocks Fall. This U.S. Company Has a Plan to Cut China Dependence. (Barrons.com)
01:07AM	Loading…
01:07AM	Daily market wrap: top stocks - Qualcomm, Keurig Dr Pepper, and Albemarle (TheStreet)
Oct-27-25 06:36PM	These stocks are falling back to Earth as Trump and China play nice (MarketWatch) -7.40%
05:50PM	Are These 3 Beaten-Down Stocks Ready to Rebound? (MarketBeat)
04:51PM	Stocks to Watch Monday: Amazon, Nvidia, Novartis, Keurig Dr Pepper (The Wall Street Journal)
04:34PM	These Stocks Are Moving the Most Today: Qualcomm, MP Materials, USA Rare Earth, Tesla, Avidity, Newmont, Microsoft, and More (Barrons.com)
04:23PM	Rare-Earth Stocks Slump. The Bad News for MP Materials and Others in a Trade Deal. (Barrons.com)
04:23PM	Does the Trump-Induced Quantum Stock Rally Have Legs? (MarketBeat)
04:18PM	Is MP Materials (MP) The Best Rare Earth Stock to Buy? (Insider Monkey)
12:00PM	Why MP Materials Stock Crashed Today (Motley Fool)
11:27AM	What we know about Trump's 'virtually done' trade deal with China so far (MarketWatch)
10:49AM	Rare Earth Stocks Hit By U.S.-China Trade Deal, But Details Await (Investor's Business Daily)
09:38AM	Stocks to Watch Monday: Nvidia, Novartis, Keurig Dr Pepper (The Wall Street Journal)
09:36AM	Should You Buy MP Materials Stock Right Now? (Motley Fool)
08:20AM	MP Stock Slumps. Why a China-US Deal Is Bad News for Rare Earths. (Barrons.com)
08:19AM	USA Rare Earth, Iren, Novartis, Softbank: Trending Stocks (Yahoo Finance Video)
08:17AM	Loading…
08:17AM	1 Incredible Reason to Buy MP Materials' Stock in November (Motley Fool)
06:08AM	MP Materials slumps, Avidity Biosciences surges and other movers (MarketWatch)
06:00AM	Interested in Rare Earth and Critical Minerals Stocks? You Might Consider Buying This ETF (Motley Fool)
05:57AM	Rare-Earths Stocks Tumble on U.S.-China Trade Progress. Why the Volatility Is Just Getting Started. (Barrons.com)
04:59AM	Stock Market Today: Dow set for 200-point rise, S&P 500 and Nasdaq to pop after weekend talks between U.S. and China (MarketWatch)
Oct-24-25 04:16PM	Rare-Earth Stocks Gain. What to Watch for Next Week. (Barrons.com)
12:45PM	Why Shares of MP Materials Are Sinking This Week (Motley Fool)
08:43AM	Rare-Earths Stocks Gain. Why Trump-Xi Meeting Won't Curb U.S. Production Drive. (Barrons.com)
Oct-23-25 06:49PM	How Trump Sparked a New Era of State Capitalism (Barrons.com)
02:00PM	U.S. Funds Tighten Grip on Canadas Oil Patch (Oilprice.com)
12:56PM	Uncle Sam Is Taking Stakes in Companies. This New Activism Is Here to Stay. (Barrons.com)
12:29PM	U.S. Gov not considering equity stakes in quantum firms, says Yahoo Finance (Investing.com)
11:38AM	Source: Trump administration not in talks to take equity stakes in quantum computing firms (Yahoo Finance)
11:06AM	MP vs. LYSDY: Which Non-China Rare-Earth Stock Has More Upside? (Zacks)
10:15AM	Two companies and one sector Team Trump could invest in next (Quartz)
09:32AM	Quantum stocks soar on report that Trump administration is discussing equity stakes in companies (Yahoo Finance)
07:00AM	U.S. Rare Earth Company Signs Strategic Deal With Japanese Government (Oilprice.com)
06:51AM	Rare-Earths Stocks Rise. The Next Big Catalyst Is Coming. (Barrons.com)
06:35AM	Rare Earths Stock Rise. The Next Big Catalyst Is Coming. (Barrons.com)
05:55AM	Quantum computing firms jump after report of US government stake talks (Reuters)
05:00AM	US-China trade spat could leave US 'weeks away' from rare earths crisis, but top defense contractors downplay risk (Yahoo Finance)
01:52AM	Trump administration in talks to take stakes in quantum-computing firms, WSJ reports (Reuters)
Oct-22-25 10:07PM	Trump administration in talks to take stakes in quantum-computing firms, WSJ reports (Reuters) -5.82%
04:21PM	MP Materials, Other Rare-Earth Stocks Drop. There Are Lots of Reasons. (Barrons.com)
07:32AM	Trump, China's Xi Are Due to Meet-But Will They? Why It Matters for Rare Earth Stocks. (Barrons.com)
07:00AM	1 Big Reason I'm Watching MP Materials Stock in 2025 (Motley Fool)
06:05AM	Whats Behind Surging Rare Earth Elements ETFs? (The Daily Upside)
01:00AM	Uncle Sam Is Taking Stakes in Companies. This New Activism Is Here to Stay. (Barrons.com)
Oct-21-25 04:09PM	What's Driving the Surge in Rare Earth Stocks (Zacks) -10.60%
03:59PM	This Rare Earths Stock Could Get a Major Trump Boost, and Analysts Think It Can Gain 40% From Here (Barchart)
02:04PM	China expert Miller: why supply chain choke points matter most (FreightWaves)
01:33PM	Trump Strikes $8.5B Rare Earths Deal to Crush China's Metals Grip (GuruFocus.com)
12:45PM	UUUU's Donald Project Gains EFA Support: Will It Fast-Track Financing? (Zacks)
11:56AM	Cleveland-Cliffs Stock Drops. Maybe It Isn't a Rare Earths Stock After All. (Barrons.com)
08:25AM	MP Materials, Other Rare-Earth Stocks Are Hot. Trump, China Can Drive Them Higher. (Barrons.com)
05:31AM	MP Materials shares pullback further from record, and other early market movers (MarketWatch)
Oct-20-25 07:06PM	Ride the Rare Earth Stock's Trade Wave? (Zacks)
04:24PM	Rare-Earths Stocks Are Up. The Focus Is on Australia, and Trump. (Barrons.com)
01:17PM	These 11 Stocks Are Probably in a Bubble. Its Time to Get Out. (Barrons.com)
11:48AM	Cleveland-Cliffs stock soars after company touts plans to 're-focus' its rare earth mining efforts (Yahoo Finance)
10:30AM	Rare Earths on the Menu as Australia's PM Meets Trump (Barrons.com)
09:53AM	USA Rare Earth, MP Materials Stocks Jump. 2 Reasons Why. (Barrons.com)
08:34AM	Cleveland-Cliffs Stock Pops. It's More Than Just Earnings. (Barrons.com)
08:23AM	USA Rare Earth Stock Jumps. Why This Analyst Says Buy Now. (Barrons.com)
08:17AM	MP Materials Shares Rise. Watch This for Clues on Where Rare Earth Stocks Go Next. (Barrons.com)
08:02AM	Buy USA Rare Earth Stock, Says Analyst. This Is Why. (Barrons.com)
07:31AM	Cleveland-Cliffs Wants Into the Rare Earths Game. The Stock Jumps. (Barrons.com)
Oct-19-25 07:33AM	Tesla, Netflix set to report earnings as US-China trade fight turns 'unsustainable': What to watch this week (Yahoo Finance)
03:06AM	The Donald Trump Administration Purchased Stakes in Intel, MP Materials, Lithium Americas, and Trilogy Metals -- and It Sets a Dangerous Precedent (Motley Fool)
Oct-18-25 07:00AM	MarketBeat Week in Review - 10/13 - 10/17 (MarketBeat)
Oct-17-25 04:14PM	MP Materials Stock Dips Again. How to Navigate the Chaos. (Barrons.com)
10:48AM	Trump Stock Market Bingo: These Miners May Be Next U.S. Equity Stakes (Investor's Business Daily)
09:53AM	Lithium Stocks: Trump Administration's Mixed Signals Hit LAC, ABAT (Investor's Business Daily)
09:26AM	BMO Capital Initiates MP Materials (MP) With a Hold Rating (Insider Monkey)
09:25AM	MP Materials Shares Dip Again. How It's Ending a Wild Week for Rare Earth Stocks. (Barrons.com)
07:00AM	China is the world leader when it comes to rare earths. This can be used this as leverage in a trade war with the U.S. (MarketWatch)
Oct-16-25 04:05PM	MP Materials Announces Date for Third Quarter 2025 Financial Results and Webcast (Business Wire) -6.69%
03:31PM	MP Materials (MP) Ends 4-Day Run, Loses 8.9% on Profit-Taking (Insider Monkey)
09:31AM	There's a New Rare-Earth Stock for Investors to Buy (Barrons.com)
08:43AM	MP Stock Rises. Rare Earth Battle Makes Dips Short Lived. (Barrons.com)
08:14AM	3 Rare Earth Stocks Powering America's Critical Minerals Boom (MarketBeat)
08:11AM	MP Materials price target raised to $112 from $78 at BofA (TipRanks)
07:17AM	MP Materials Stock Rises as Bessent Gives Hope on China Trade and Rare Earths (Barrons.com)
06:32AM	What Is One of the Best Industrials Stocks to Buy Now? (Motley Fool)
Oct-15-25 04:12PM	MP Materials Stock Snapped a 4-Day Winning Streak. Whats Drove Shares Lower. (Barrons.com) -8.92%
12:25PM	Can Energy Fuels Lead America's Drive for Rare Earth Independence? (Zacks)
10:23AM	MP Materials Stock Could Snap a 4-Day Winning Streak. Whats Driving Shares Lower. (Barrons.com)
09:07AM	MP Materials Stock Could Snap a 4-Day Winning Streak. What's Driving Shares. (Barrons.com)
08:11AM	Trump Stock Market Bingo: These 25 Miners May Be Next U.S. Equity Stakes (Investor's Business Daily)
06:03AM	Zacks Investment Ideas feature highlights: Lithium Americas, MP Materials, USA Rare Earth, Trilogy Metals and JPMorgan Chase (Zacks)

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rosenthal Michael Stuart	Chief Operating Officer	Aug 29 '25	Sale	72.02	150,000	10,802,838	1,284,409	Aug 29 09:23 PM
Rosenthal Michael Stuart	Officer	Aug 29 '25	Proposed Sale	72.02	150,000	10,803,255		Aug 29 04:20 PM
Hoops Elliot Dean	General Counsel and Secretary	Aug 01 '25	Sale	60.33	6,337	382,304	0	Aug 01 09:22 PM
Hoops Elliot Dean	Officer	Aug 01 '25	Proposed Sale	60.29	6,337	382,038		Aug 01 03:58 PM
Hoops Elliot Dean	General Counsel and Secretary	Jul 01 '25	Sale	31.94	6,338	202,464	6,337	Jul 03 09:27 PM
Hoops Elliot Dean	Officer	Jul 01 '25	Proposed Sale	31.90	6,338	202,209		Jul 01 04:36 PM
Hoops Elliot Dean	General Counsel and Secretary	Jun 26 '25	Sale	36.37	5,523	200,872	69,749	Jun 27 09:30 PM
Hoops Elliot Dean	Officer	Jun 26 '25	Proposed Sale	36.33	5,523	200,651		Jun 26 04:17 PM
Hoops Elliot Dean	General Counsel and Secretary	Jun 13 '25	Sale	29.96	5,538	165,918	12,675	Jun 13 09:25 PM
Hoops Elliot Dean	General Counsel and Secretary	Jun 12 '25	Sale	29.95	800	23,960	18,213	Jun 13 09:25 PM
Hoops Elliot Dean	Officer	Jun 13 '25	Proposed Sale	29.96	6,338	189,900		Jun 13 04:30 PM
Litinsky James H.	Chairman and CEO	Apr 14 '25	Sale	27.08	199,180	5,393,794	13,643,076	Apr 16 09:11 PM
Litinsky James H.	Chairman and CEO	Mar 25 '25	Sale	27.03	396,293	10,711,800	13,860,775	Mar 27 09:40 PM
Litinsky James H.	Chairman and CEO	Mar 26 '25	Sale	27.00	18,519	500,013	13,842,256	Mar 27 09:40 PM
Litinsky James H.	Chairman and CEO	Mar 20 '25	Sale	27.04	95,621	2,585,592	14,257,068	Mar 21 09:15 PM
Litinsky James H.	Chairman and CEO	Mar 18 '25	Sale	26.71	639,294	17,075,543	14,513,864	Mar 19 09:18 PM
Litinsky James H.	Chairman and CEO	Mar 17 '25	Sale	26.77	489,918	13,115,105	15,153,158	Mar 19 09:18 PM
Litinsky James H.	Chairman and CEO	Mar 19 '25	Sale	26.94	161,175	4,342,054	14,352,689	Mar 19 09:18 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Mar 19 '25	Proposed Sale	26.83	788,356	21,151,591		Mar 19 05:04 PM
Corbett Ryan	Chief Financial Officer	Mar 14 '25	Sale	25.51	60,000	1,530,391	230,100	Mar 18 06:45 PM
Corbett Ryan	Chief Financial Officer	Mar 17 '25	Sale	27.00	15,000	405,000	214,812	Mar 18 06:45 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Mar 18 '25	Proposed Sale	26.69	721,726	19,262,867		Mar 18 05:06 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Mar 17 '25	Proposed Sale	26.83	489,918	13,144,500		Mar 17 05:05 PM
Corbett Ryan	Officer	Mar 17 '25	Proposed Sale	27.00	15,000	405,000		Mar 17 04:03 PM
Corbett Ryan	Officer	Mar 14 '25	Proposed Sale	25.00	60,000	1,500,000		Mar 14 04:09 PM
Litinsky James H.	Chairman and CEO	Feb 04 '25	Sale	24.01	386,223	9,273,214	15,643,076	Feb 06 09:13 PM
Litinsky James H.	Chairman and CEO	Dec 03 '24	Sale	23.39	1,579,110	36,934,246	16,029,299	Dec 04 07:37 PM
Litinsky James H.	Chairman and CEO	Dec 02 '24	Sale	20.68	234,667	4,852,914	17,608,409	Dec 04 07:37 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Dec 03 '24	Proposed Sale	20.81	1,200,000	24,972,000		Dec 03 05:01 PM
Litinsky James H.	Chairman and CEO	Nov 26 '24	Sale	20.22	300,000	6,066,000	18,043,076	Nov 29 07:11 PM
Litinsky James H.	Chairman and CEO	Nov 27 '24	Sale	20.90	200,000	4,180,000	17,843,076	Nov 29 07:11 PM
Corbett Ryan	Chief Financial Officer	Nov 29 '24	Sale	21.50	35,000	752,500	260,021	Nov 29 07:00 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Nov 29 '24	Proposed Sale	20.84	1,000,000	20,840,000		Nov 29 01:54 PM
Corbett Ryan	Officer	Nov 29 '24	Proposed Sale	21.50	35,000	752,500		Nov 29 01:12 PM
JAMES HENRY LITINSKY REVOCABLE	Officer	Nov 27 '24	Proposed Sale	20.90	200,000	4,180,420		Nov 27 04:22 PM
JAMES HENRY LITINSKY REVOCABLE	Officer	Nov 26 '24	Proposed Sale	20.22	300,000	6,064,680		Nov 26 04:41 PM
Litinsky James H.	Chairman and CEO	Nov 18 '24	Sale	18.45	300,000	5,535,000	18,221,776	Nov 18 09:35 PM
Corbett Ryan	Chief Financial Officer	Nov 18 '24	Sale	18.30	15,195	278,068	295,021	Nov 18 09:28 PM
Hoops Elliot Dean	General Counsel and Secretary	Nov 15 '24	Sale	18.03	30,000	540,900	8,114	Nov 18 09:23 PM
JAMES HENRY LITINSKY REVOCABLE	Officer	Nov 18 '24	Proposed Sale	18.45	300,000	5,534,760		Nov 18 04:19 PM
Ryan S Corbett	Officer	Nov 18 '24	Proposed Sale	18.29	15,195	277,923		Nov 18 02:13 PM
HOOPS FAMILY TRUST	Officer	Nov 15 '24	Proposed Sale	18.03	30,000	540,921		Nov 15 04:56 PM

ROIV

Roivant Sciences Ltd

MP

MP Materials Corporation

Upgrade your FINVIZ experience